Description
He is leading groundbreaking research on the underlying mechanisms of nerve damage in patients with diabetes and the link between Alzheimer’s disease and Type 2 diabetes. Through his studies, Dr. Fernyhough is identifying key signaling pathways that are impaired in animal models of neuropathy and Alzheimer’s disease, with the goal of developing new treatments for these debilitating conditions. As the World Health Organization predicts that by 2025 there will be 300 million sufferers from diabetes worldwide, the impact of Dr. Fernyhough’s research has the potential to be truly significant. He is affiliated with several research groups, including Diabetes Action Canada, WinSanTor Inc. and Manitoba Neuroscience Network, where his research is making a real impact in the field of diabetic complications and peripheral neuropathy. He is also known for his research on cholinergic signaling, GPCR signaling, bioenergetics and drug design, which is helping to further our understanding of these complex conditions.
